When nanomedicines meet tropical diseases
Prof. Eder Lilia Romero, University of Quilmes, Buenos Aires, Argentina
Prof. Fabio Rocha Formiga, Oswaldo Cruz Foundation, University of Pernambuco and Aggeu Magalhães Institute, Recife, Brazil
Dr. Katrien Van Bocxlaer, The University of York, United Kingdom
Prof. Fabio Rocha Formiga, Oswaldo Cruz Foundation, University of Pernambuco and Aggeu Magalhães Institute, Recife, Brazil
Dr. Katrien Van Bocxlaer, The University of York, United Kingdom
This thematic issue will cover the latest pre-clinical approaches (in silico, purely in vitro and in vivo models), employing chemotherapeutic or prophylactic nanomedicines against tropical diseases, including, but not limited to:
- Chagas disease,
- Muco-cutaneous and visceral leishmaniasis,
- Dengue,
- Filariasis,
- Mycetoma,
- Schistosomiasis,
- Sleeping sickness and
- Malaria
Submission Deadline: August 31, 2023
Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies
- Giuliana Muraca,
- María Esperanza Ruiz,
- Rocío C. Gambaro,
- Sebastián Scioli-Montoto,
- María Laura Sbaraglini,
- Gisel Padula,
- José Sebastián Cisneros,
- Cecilia Yamil Chain,
- Vera A. Álvarez,
- Cristián Huck-Iriart,
- Guillermo R. Castro,
- María Belén Piñero,
- Matias Ildebrando Marchetto,
- Catalina Alba Soto,
- Germán A. Islan and
- Alan Talevi
Beilstein J. Nanotechnol. 2023, 14, 804–818, doi:10.3762/bjnano.14.66
Green SPIONs as a novel highly selective treatment for leishmaniasis: an in vitro study against Leishmania amazonensis intracellular amastigotes
- Brunno R. F. Verçoza,
- Robson R. Bernardo,
- Luiz Augusto S. de Oliveira and
- Juliany C. F. Rodrigues
Beilstein J. Nanotechnol. 2023, 14, 893–903, doi:10.3762/bjnano.14.73
Other Beilstein-Institut Open Science Activities
